Ythdf2-flox 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Ythdf2-flox 基因敲除小鼠

产品编号

S-CKO-05737

品系全称

C57BL/6JCya-Ythdf2em1flox/Cya

品系背景

C57BL/6JCya

品系编号

CKOCMP-213541-Ythdf2-B6J-VA

品系状态

使用本品系发表的文献需注明: Ythdf2-flox 基因敲除小鼠 mice (Strain S-CKO-05737) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
cKO小鼠库模型

基本信息

基因研究概述

质控标准

基因
基因全称
YTH N6-methyladenosine RNA binding protein 2
基因别称
9430020E02Rik,HGRG8,NY-REN-2
染色体号
Chr 4 (Mouse)
转录本 ID
NCBI: NM_145393 | Ensembl: ENSMUST00000152796
修饰方式
条件性基因敲除
靶向范围
Exon 3
敲除长度
~0.6 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:2444233Mice homozgyous for a knock-out allele exhibit female, but not male, infertility and preweaning lethality that is background sensitive. Homozygous KO male mice are hypo-fertile.

发表文献

Advanced Science
2024-01-20
YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis
1
Ythdf2,也称为YTH domain family 2,是一种重要的RNA结合蛋白(RBP),属于YTH结构域家族。Ythdf2主要在细胞质中发挥功能,它能够识别并结合N6-甲基腺苷(m6A)修饰的RNA,进而影响RNA的稳定性和翻译效率。m6A是一种普遍存在于真核细胞RNA上的表观遗传修饰,参与调控RNA的稳定性和功能,影响基因表达和生物学过程。Ythdf2通过与m6A修饰的RNA结合,促进这些RNA的降解,从而抑制基因表达。

在多种癌症中,Ythdf2的表达水平与肿瘤的发生和进展密切相关。例如,在眼黑色素瘤中,组蛋白乳酸化水平升高,促进了Ythdf2的表达,进而导致肿瘤的发生[1]。在肺癌中,RNA甲基转移酶KIAA1429的表达上调,通过m6A-Ythdf2依赖机制促进肿瘤的发生[2]。在乳腺癌中,抑制Ythdf2的表达可以触发凋亡,抑制肿瘤的发生[3]。在胶质母细胞瘤中,Ythdf2的表达上调,通过促进胆固醇代谢紊乱和侵袭性生长,促进了肿瘤的发生[4]。在内肝胆管癌中,Ythdf2的表达上调,通过促进CDKN1B mRNA的降解,促进了肿瘤的发生和化疗耐药[5]。在肝细胞癌中,Ythdf2的表达上调,通过调节OCT4的表达,促进了肿瘤的发生和转移[6]。此外,Ythdf2还可以通过SUMO化修饰增加其与m6A修饰的RNA的结合亲和力,从而促进RNA的降解和肿瘤的进展[7]。

综上所述,Ythdf2是一种重要的RNA结合蛋白,它能够识别并结合m6A修饰的RNA,进而影响RNA的稳定性和翻译效率。Ythdf2在多种癌症中发挥重要作用,它的表达上调与肿瘤的发生和进展密切相关。因此,Ythdf2可能成为癌症治疗的新靶点,通过抑制Ythdf2的表达或功能,可以抑制肿瘤的发生和进展。

参考文献:
1. Yu, Jie, Chai, Peiwei, Xie, Minyue, Fan, Xianqun, Jia, Renbing. 2021. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. In Genome biology, 22, 85. doi:10.1186/s13059-021-02308-z. https://pubmed.ncbi.nlm.nih.gov/33726814/
2. Zhang, Chang, Sun, Qi, Zhang, Xu, Tan, Fengwei, Shen, Hongbing. 2022. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma. In Cancer communications (London, England), 42, 609-626. doi:10.1002/cac2.12325. https://pubmed.ncbi.nlm.nih.gov/35730068/
3. Einstein, Jaclyn M, Perelis, Mark, Chaim, Isaac A, Westbrook, Thomas F, Yeo, Gene W. 2021. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. In Molecular cell, 81, 3048-3064.e9. doi:10.1016/j.molcel.2021.06.014. https://pubmed.ncbi.nlm.nih.gov/34216543/
4. Fang, Runping, Chen, Xin, Zhang, Sicong, He, Chuan, Huang, Suyun. 2021. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. In Nature communications, 12, 177. doi:10.1038/s41467-020-20379-7. https://pubmed.ncbi.nlm.nih.gov/33420027/
5. Huang, Chen-Song, Zhu, Ying-Qin, Xu, Qiong-Cong, Zhao, Wei, Yin, Xiao-Yu. . YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. In Clinical and translational medicine, 12, e848. doi:10.1002/ctm2.848. https://pubmed.ncbi.nlm.nih.gov/35696608/
6. Zhang, Chuanzhao, Huang, Shanzhou, Zhuang, Hongkai, Hou, Baohua, He, Xiaoshun. 2020. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. In Oncogene, 39, 4507-4518. doi:10.1038/s41388-020-1303-7. https://pubmed.ncbi.nlm.nih.gov/32366907/
7. Hou, Guofang, Zhao, Xian, Li, Lian, Jiang, Bin, Yu, Jianxiu. . SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. In Nucleic acids research, 49, 2859-2877. doi:10.1093/nar/gkab065. https://pubmed.ncbi.nlm.nih.gov/33577677/

发表文献

点击查看发表文献 >>